Professor of Medicine (AIDS), Yale School of Medicine
Frederick Altice, MD, is Professor of Medicine at Yale University School of Medicine in New Haven, Connecticut. He is the Director of Clinical and Community Research of the Yale University AIDS Program for the School of Medicine, where he also directs the Community Health Care Van and the HIV in Prisons Program.
Dr. Altice's research interests are focused on the interface between infectious diseases and substance abuse. As a clinical epidemiologist, health services and intervention researcher, he has created novel programs for the treatment of HIV, HCV, and tuberculosis in vulnerable populations, including injection drug users and prison inmates. Specifically, he has been an international leader in research related to adherence to antiretroviral therapy, particularly among HIV+ drug users, has made considerable inroads into novel approaches using directly administered antiretroviral therapy and other structural interventions to facilitate adherence both nationally and internationally.
Dr. Altice has been at the forefront of integrating buprenorphine and methadone treatment into managing co-morbid conditions, including the management of HIV, HCV, TB and mental illness. He is the Principal Investigator on over 15 federally-funded grants, including numerous clinical investigations funded by the National Institutes on Health, the Substance Abuse and Mental Health Services Administration, Special Projects of National Significance for the Health Resources Services Agency and other federal agencies, Dr. Altice is currently leading studies that bridge the gap between the correctional and community setting, specifically on the use of directly observed antiretroviral therapy and opiate-substitution therapy. In addition to publishing his research in peer-reviewed journals, Dr. Altice has authored several significant books and book chapters. He lectures nationally and internationally on the subject of HIV, viral hepatitis, substance abuse and the management of medically complicated patients.
Current research includes methadone and buprenorphine as primary and secondary HIV prevention, directly administered antiretroviral therapy, peer-driven interventions, secondary prevention among drug users and prisoners and includes international projects in Malaysia, Ukraine and Iran.
